Giant Cell Arteritis clinical trials

The registry lists 147 studies for Giant Cell Arteritis across more than 10 countries. 49 are recruiting or about to start. 109 of them are mainly about Giant Cell Arteritis (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-30.

Get an email when these change. Save the Giant Cell Arteritis studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 62
Recruiting: 36
Status unknown: 14
Terminated: 13
Not yet recruiting: 11
Active, not recruiting: 7

Phase

Phase 2: 23
Phase 3: 20
Phase 1: 8
Phase 4: 6
Early Phase 1: 1

Where

France: 54
United States: 35
Germany: 22
Canada: 21
Denmark: 18
United Kingdom: 16

Who runs them

Centre Hospitalier Universitaire Dijon (11) · University of Pennsylvania (7) · University of South Florida (5) · University of Bonn (5) · University of Oxford (4) · Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal (4) · University Hospital, Brest (4) · University of Aarhus (4)

What is being tested here

Drugs under test in Giant Cell Arteritis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Tocilizumab	2	3	12
Abatacept	2	2	4
Bosentan	2	0	2
Hydrocortisone	2	0	2
Secukinumab	1	2	5
Prednisone	1	3	4
Methotrexate	1	0	3
Upadacitinib	1	1	2
Adalimumab	1	1	2
Infliximab	1	0	2

Drug classes tested here Corticosteroids 3 open · Antimetabolites 1 open · JAK inhibitors 1 open · Tyrosine kinase inhibitors (TKIs) 1 open

Coming up

6phase 3 studies under way

7studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 7

Dec 2026Performance of a Fast-track Pathway for Giant Cell Arteritis Diagnosis · Groupe Hospitalier de la Rochelle Ré Aunis
Mar 2027The Applanation Tonometry in GCA Pilot · Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
Apr 2027Post-therapeutic Imaging Evaluation of Patients With Horton's Disease (Giant Cell Arteritis) (EvHortim) · Fondation Ophtalmologique Adolphe de Rothschild
Jun 2027Impact of the Spatial Resolution of Several Contrast-enhanced 3D T1-WI Sequences When Diagnosing Giant Cell Arteritis (GCA) · Fondation Ophtalmologique Adolphe de Rothschild
Jun 2027Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis · National Institute of Allergy and Infectious Diseases (NIAID)
Jul 2027Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV) · University of Edinburgh
Oct 2027Pilot Study to evaluateThrombomodulin to Rule Out Giant Cell Arteritis (GCA) in Polymyalgia Rheumatica (PMR) Patients. (THROPIQ) · Centre Hospitalier Universitaire Dijon

Who these studies take

Of the 36 Giant Cell Arteritis studies recruiting now, 34 (94%) set no upper age limit and 0 (0%) stop at 75 or younger. 4 (11%) take children under 18. 0 (0%) are for women only and 1 (3%) for men only; 9 (25%) take healthy volunteers.

Recruiting studies that take each age, of 36
Age	Women	Men
10	4 (11%)	4 (11%)
18	17 (47%)	17 (47%)
30	17 (47%)	17 (47%)
40	17 (47%)	17 (47%)
50	35 (97%)	36 (100%)
65	35 (97%)	36 (100%)
75	35 (97%)	36 (100%)
85	35 (97%)	36 (100%)

Across all 147 studies, recruiting or not: 1% stop at 75 or younger and 1% at 65; 10% take children; 0% are for women only and 1% for men only; 18% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Giant Cell Arteritis studies take

Of 44 observational studies under Giant Cell Arteritis, half reached primary completion within 45 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Observational	45 mo33–164 · 44 studies	—	—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Started recruiting1

Early Temporal Dynamics of Optic Nerve Sheath Diameter After Therapy in GCAOct 21, 2026NCT07508514

Newly registered1

Aspirin for the Prevention of Ischemic Complications in Giant Cell ArteritisOct 30, 2026NCT07908082

Studies

Recruiting first, then most recently updated. Showing 50 of 147. Browse all 147 → or search them.